Related Experiment Video
Updated: Jun 14, 2026
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
High-Dose Docosahexaenoic Acid in Newborns Born at Less Than 29 Weeks' Gestation and Behavior at Age 5 Years:
Jacqueline F Gould1,2,3, Rachel M Roberts3, Peter J Anderson4
1SAHMRI Women and Kids, South Australian Health and Medical Research Institute, North Adelaide, South Australia, Australia.
Insights
Supplementing very premature infants with docosahexaenoic acid (DHA) did not improve behavioral outcomes at age 5. This randomized trial found no adverse effects from DHA supplementation in extremely preterm children.
Area of Science:
- Neonatal care
- Neuroscience
- Nutritional science
Background:
- Infants born before 29 weeks gestation are at risk for behavioral issues.
- Docosahexaenoic acid (DHA) is crucial for brain development and may be lacking in preterm infants.
Purpose of the Study:
- To investigate if neonatal DHA supplementation improves behavioral functioning in children born before 29 weeks gestation.
- To assess the impact of meeting neonatal DHA requirements on long-term behavioral outcomes.
Main Methods:
- A follow-up of a randomized clinical trial involving infants born at less than 29 weeks gestation.
- Infants received either DHA or a soy-oil placebo until 36 weeks postmenstrual age or discharge.
- Parent-completed questionnaires assessed behavior and executive functioning at 5 years corrected age.
Main Results:
- No significant difference in the Total Difficulties score (primary outcome) between DHA and placebo groups.
- Mean scores were identical (11.8) in both groups at 5-year follow-up.
- No differences observed in secondary behavioral, executive functioning, or health outcomes.
Conclusions:
- Enteral DHA supplementation did not enhance behavioral functioning in children born extremely preterm at age 5.
- The study found no evidence of adverse effects associated with DHA supplementation in this population.
Importance:
Children born at less than 29 weeks' gestation are at risk of behavioral difficulties. This may be due in part to the lack of transplacental supply of docosahexaenoic acid (DHA), a key fatty acid with structural and functional roles in the brain.
Objective:
To determine whether meeting the neonatal DHA requirement through supplementation is associated with improved behavioral functioning of children born at less than 29 weeks' gestation.
Design, Setting And Participants:
This was a follow-up of children from 10 Australian participating centers in a multi-center, blinded, parallel group randomized clinical trial of infants born at less than 29 weeks' gestation conducted from June 2012 and September 2015, excluding those with additional fatty acid supplementation or major congenital or chromosomal abnormalities. Follow-up took place from August 2018 to May 2021. Parents of surviving children who had not withdrawn from the original trial were invited to complete questionnaires when the child turned 5 years' corrected age.
Interventions:
Infants were randomized to receive daily enteral emulsions providing 60 mg/kg/d of DHA or a soy-oil emulsion (with no DHA) from within the first 3 days of enteral feeding until 36 weeks' postmenstrual age or discharge home, whichever occurred first.
Main Outcomes And Measures:
The primary outcome of this follow-up was parent-rated behavior and emotional functioning as indicated by the Total Difficulties score of the Strengths and Difficulties Questionnaire. Parents also completed questionnaires about their child's behavioral manifestations of executive functioning, as well as a range of health outcomes to assess potential longer-term side effects of DHA intervention.
Results:
Primary outcome data were available for 731 children (76% of 958 surviving eligible children; 361 in the intervention group and 370 in the control group). Of these 731, 452 (47%) were female, and the mean (SD) corrected age at follow-up was 5.4 (0.5) years. Following imputation for missing data, the mean Total Difficulties score was the same in both groups (intervention group, n = 465; mean [SD], 11.8 [6.3]; control group, n = 493; mean [SD], 11.8 [6.0]; mean difference adjusted for sex, gestational age stratum, and hospital, 0.01; 95% CI, -0.87 to 0.89; P = .98). There was no evidence for differences between the groups in any secondary outcomes of behavior, executive functioning, or health.
Conclusions And Relevance:
In this follow-up of a randomized clinical trial, enteral DHA supplementation at the equivalent of the estimated in utero dose for infants born at less than 29 weeks' gestation did not improve behavioral functioning at age 5 years. There were no indications of adverse effects with DHA supplementation.
Trial Registration:
Australian New Zealand Clinical Trial Registry: ACTRN12612000503820.
More Related Videos
03:19Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Related Concept Videos
01:07Teratogenicity
01:29Drug Dosing: Infants and Children